This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
SOURCE: Eqalix, Inc.
Eqalix has announced the expansion of its pre-clinical research and development efforts through a Sponsored Research Agreement with Temple University’s Department of Bioengineering.
Reston, VA (PRWEB) December 11, 2012
Under the agreement, Eqalix and Temple Bioengineering Chair and Professor Peter I. Lelkes will jointly advance the development of its three breakthrough technologies for regenerative medicine – protein-based skin substitute, regenerative blood vessels and nerve endings and regeneration of damaged and traumatized organs.
“This arrangement with Temple University works well with our strategy as an emerging company to maintain low overhead costs while accessing leading scientific expertise for the development of our product candidates,” said Eqalix Chairman and CEO Joseph P. Connell. “At the same time, we are building another example of a collaborative effort between the private sector and academia to further the development of novel approaches to treat diseases requiring improved therapies that will address the unmet needs of patients.”
Eqalix is an emerging regenerative medicine development company with a goal of enhancing the quality of life of consumers and patients by providing novel nano-materials for the repair and regeneration of diseased, traumatized and aging tissues. Its innovative technologies are intended to revolutionize the unmet needs in multiple commercial and therapeutic applications in the Regenerative Medicine space.
“We are excited and enthusiastic about entering into a Sponsored Research Agreement with a visionary start-up company such as Eqalix that will entail groundbreaking research in regenerative engineering, as well as the development of innovative and affordable products for wound care and cosmetic applications alike,” said Lelkes, who also serves as director of the Institute for Regenerative Medicine and Engineering in Temple’s School of Medicine.
Eqalix has received exclusive commercial licensing from other Philadelphia institutions for several groundbreaking technologies being developed in the fields of aesthetic dermatology, the consumer market for beauty and skin care, acute and chronic wounds requiring skin replacement, vascular replacements and the repair of traumatic damage to peripheral nerves.
Eqalix plans to leverage these technologies to develop and commercialize: a) plant protein-based nano-fiber scaffolds for use in aesthetic dermatology and wound healing markets; b) small-diameter hybrid vessels that reduce graft thrombogenicity and promote the creation of a functional endothelium after implantation; and c) three-dimensional tissue scaffolds with tunable properties for tissue and organ replacement and repair.
The technologies move the bar higher and intend to replicate the function of damaged, diseased or aging tissues by providing “implants” or scaffolds that are non-immunogenic, bio-compatible, and intended to restore the features and function of the damaged tissue by using the body’s own repair mechanisms. Eqalix is attempting to create skin without scarring and contraction, blood vessels without clotting, repair of injured nerves and organ beyond current capabilities.
“These lofty goals, although seemingly futuristic, are in the immediate realm of scientific possibilities today --- and at Eqalix,” said Connell.
Temple’s new bioengineering department was established in January 2012. Housed in the College of Engineering, Temple’s fastest growing college, the department seeks to provide a well-rounded, in-depth education and a world-class research experience at the interface of engineering, the life sciences and medicine, with the goal of promoting scientific discovery, as well as the development of new technologies that will benefit humanity.
Eqalix, Inc. is a privately held Virginia based C-Corporation located in Reston, VA.
Contact: Joseph P. Connell, 910-233-0806; jconnell (at) eqalix (dot) com
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/12/prweb10213704.htm